Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,175.00 at Evercore ISI

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target reduced by Evercore ISI from $1,250.00 to $1,175.00 in a research report sent to investors on Thursday morning, Benzinga reports. Evercore ISI currently has an outperform rating on the biopharmaceutical company’s stock.

Other analysts also recently issued reports about the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. Finally, Piper Sandler raised their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,101.00.

Regeneron Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ REGN traded up $10.18 during mid-day trading on Thursday, reaching $939.08. The company had a trading volume of 35,514 shares, compared to its average volume of 502,230. The stock has a market capitalization of $103.52 billion, a PE ratio of 24.60, a price-to-earnings-growth ratio of 3.29 and a beta of 0.12. Regeneron Pharmaceuticals has a twelve month low of $769.19 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The stock’s 50 day moving average is $1,098.29 and its 200-day moving average is $1,040.67.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.79 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals will post 37.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $26,000. Sachetta LLC increased its position in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $28,000. Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at about $33,000. Finally, Family Firm Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.